Skip to main content
Journal of Assisted Reproduction and Genetics logoLink to Journal of Assisted Reproduction and Genetics
. 2018 Sep 15;35(12):2121–2128. doi: 10.1007/s10815-018-1305-3

Connecting links between genetic factors defining ovarian reserve and recurrent miscarriages

Deepika Delsa Dean 1, Sarita Agarwal 1,, Poonam Tripathi 1
PMCID: PMC6289926  PMID: 30219969

Abstract

Purpose

Approximately 1–2% of the women faces three or more successive spontaneous miscarriages termed as recurrent miscarriage (RM). Many clinical factors have been attributed so far to be the potential risk factors in RM, including uterine anomalies, antiphospholipid syndrome, endocrinological abnormalities, chromosomal abnormalities, and infections. However, in spite of extensive studies, reviews, and array of causes known to be associated with RM, about 50% cases encountered by treating physicians remains unknown. The aims of this study were to evaluate recent publications and to explore oocyte-specific genetic factors that may have role in incidence of recurrent miscarriages.

Method

Recent studies have identified common molecular factors contributing both in establishment of ovarian reserve and in early embryonic development. Also, studies have pointed out the relationship between the age-associated depletion of OR and increase in the risk of miscarriages, thus suggestive of an interacting biology. Here, we have gathered literature evidences in establishing connecting links between genetic factors associated with age induced or pathological OR depletion and idiopathic RM, which are the two extreme ends of female reproductive pathology.

Conclusion

In light of connecting etiological link between infertility and RM as reviewed in this study, interrogating the oocyte-specific genes with suspected roles in reproductive biology, in cases of unexplained RM, may open new possibilities in widening our understanding of RM pathophysiology.

Keywords: Recurrent miscarriages, Ovarian reserve, Premature ovarian insufficiency, Genetic, Factors

Introduction

Miscarriage, which is widely defined as a spontaneous loss of pregnancy before 20 weeks of gestation [1, 2], is recognized as the most common complication of pregnancy affecting 2–5% of couples [3]. About 15% of all clinically recognizable pregnancies terminates in a miscarriage [4] while preclinical miscarriages take place in approximately 60% of human conceptions and are lost very early, i.e., near or following implantation [4]. Approximately 1–2% of the women faces three or more successive spontaneous miscarriages termed as recurrent miscarriage (RM) [57] leaving them in a devastating and emotionally taxing situation [8, 9]. The possibility of having another miscarriage tends to increase with history of previous miscarriages [10]. Such incidence of repeated miscarriages in a women seems not to be a result of chance but is suggestive of some underlying abnormality.

The known causes of RM

Many clinical factors have been attributed so far to be potential risk factors in RM. In 15% of the women facing RM, an anatomical abnormality could be involved, with septate uterus being most common [11]. Immunological blood clotting disorder like antiphospholipid syndrome (APS) is found associated with another 15% of RM cases causing 1st and 2nd trimester miscarriages [1, 3]. Several endocrinological abnormalities have also been implicated as etiologic factors for about 8 to 12% of RM [12]. This is due to poorly controlled and untreatable hormonal imbalances, as in disorders like diabetes mellitus [13, 14], hypothyroidism [15, 16], and luteal phase deficiency [17] which may have deleterious effects in implantation of growing embryo. In 2–4% of RM cases, balanced chromosomal translocations in asymptomatic parents may result in generation of unbalanced translocation in conceptuses [18]. These are often negatively selected by nature and mostly end up in a miscarriage [19, 20]. Several infections have been also identified as potential cause of early miscarriage [21] with specifically, 15% of early miscarriages and 66% of late miscarriages been associated with infections [22].

The unknown cause of RM

In spite of extensive studies, reviews, and array of causes known to be associated with RM, about 50% cases encountered by treating physicians remains unexplained, idiopathic, or unknown. The challenge of identifying underlying cause in these perplexing cases is huge and urges researchers to put in efforts to know more, explore more, and relate more. There might be some related pathways that remained either unquarried or underexplored in defining their potential role in RM till date. One such entity that might affect the embryo development is the molecular factors associated with the establishment of the ovarian reserve (OR). OR is the quantity and quality of the ovarian primordial follicular pool remaining in a women’s ovaries. The relationship of age-associated depletion of OR and increase in the risk of miscarriage and also role of various oocyte-specific genes in early embryonic development and in embryo implantation is suggestive of interacting biology [23, 24]. This review aims to gather evidences in establishing connecting links between genetic factors associated with age induced or pathological OR depletion and idiopathic RM, which are the two extreme ends of female reproductive pathology. This will facilitate in identifying possible candidates in the RM pathophysiology and may lead to provide possible explanation for many of the unclassified RM cases.

Biological ovarian age and risk of miscarriages

Recent decades have witnessed an increase in the mean maternal age at the time of childbirth in developed countries [25]. Advanced maternal age has long been linked with increasing incidence of RM. For example, miscarriage risk of 9 to 12% is found in a women ≤ 35 years, but this risk upsurges to 75% in women with age > 40 [26]. The ovaries of a women exhibit accelerated aging in comparison to other biological system and therefore result in deterioration of OR both in number and quality of the oocytes. In fact, an exponential relationship has been observed between maternal age and presence of chromosomal abnormality in oocytes, with about 40–60% of oocytes from women of 40 years being aneuploids [27, 28]. Subsequently, such oocytes after fertilization translate into compromised quality embryos. Recently, Quenby et al. suggested that RM is a failure of nature’s quality control that allows poor quality embryos to implant inappropriately, present as clinical pregnancy, and then undergo miscarriages [29]. This is evident from the fact that about 40–50% of miscarriages in the first trimester are result of chromosomal abnormalities in the conceptuses [30, 31].

Also, it was observed that assisted reproductive technology (ART) methods often fail for older women using their own oocytes, while donor oocytes from younger women can be successfully used in these women [32]. Reports depicting the potential of postmenopausal women to act as a successful surrogate have also been identified previously [3336]. Similarly, with the help of ART, cases where post-menopausal women have given birth to healthy offspring have become quite common. These findings establish that parameters associated with decreased fertility appear to be present majorly within oocyte itself rather than the uterine environment. Therefore, understanding the genetic factors affecting the oocyte quality and quantity and further in embryo development is important to define its role in compromised fertility.

Apart from age-related physiologic depletion of OR in women of more than 40 years of age, a premature reduction of OR (pathological OR depletion) has also been identified in a subset of women suffering with diminished ovarian reserve (DOR). DOR is defined as reduced capacity of the ovaries to produce oocytes and is characterized by an abnormal OR testing with decreased antral follicle count (AFC < 5) on ultrasound, reduced anti-müllerian hormone (AMH < 0.5–1 ng/mL), or higher levels of follicle stimulating hormone (FSH > 10 IU/L on cycle days 2 to 4) [37, 38]. Toukhy et al. in 2002 enrolled 762 women with DOR and classified them in three different age groups of young, intermediate, and old. The miscarriage rate was found to be similarly high in all these three groups. The results of this study depicted that it is not the chronological age which is important; instead, it is the biological age of the ovary that dictates the pregnancy outcome and also, that the young age of a women does not protect her against the adverse effect of reduced OR [39]. In some women, a severe form of DOR can be present called as premature ovarian insufficiency (POI), characterized by 4 months of amenorrhea and day 3 FSH to be > 40 IU/L. Once the diagnosis of POI is reached, the women’s reproductive potential is completely exhausted and women enter an early age menopause before 40 years. As quantity and quality of the oocytes and thereby the reproductive potential of a women go on depleting [40] and ultimately come to an end at natural menopause, thus it is likely that a diagnosis of POI (complete cessation of fertility) may be preceded by RM due to compromised oocyte quality with an augmented meiotic non-disjunction and subsequent generation of aneuploidy of embryos, which is one of the main causes of spontaneous miscarriages [4144]. In fact, a study by Santos et al., in 2015, observed that the oocyte in women with elevated FSH (prone to POI) is of worst quality in comparison to age-matched control women. Here, the author concluded that these oocytes of compromised quality are indicative of ovarian aging and may negatively affect the oocyte development into viable embryos leading to frequent miscarriages. Another recent study reported that percentage of women with elevated FSH was higher in the women undergoing RM, as compared to age-matched control women, and thereby recommended the association of DOR and RM [45]. The association of oocyte quality and RM in both physiological (normal aging) and pathological depletion of OR (DOR or POI) cases suggest that they may share common etiological pathways. Exploring the molecular pathways related to physiological aging and the pathologic disorders of oocyte quality would give researchers and clinicians the ability to improve fertility and pregnancy outcomes for many women.

Genetic factors involved in launch of OR and their putative role in RM

The OR decreases constantly, from fetal life, when it is established, until the menopause. The fetal number of oocytes is approximately 7 million during mid-gestation, 1 to 2 million at birth which further drops down to only 0.3–0.5 million at puberty [4648]. A women can ovulate about 500 times in her lifetime, and a majority of oocytes undergo atresia; thus, perimenopausal women’s ovaries are left with only approximately 1000 oocytes of compromised quality [49, 50]. The overall process of OR establishment, pubertal OR activation, and age-dependent or pathological depletion of OR is largely influenced by genetic parameters. An alteration in the genes underlying these processes may lead to a spectrum of impaired ovarian function including POI. Till date, several causative mutations in various oocyte-specific genes have been implicated in POI rendering women infertile [51, 52].

Researchers have noted that there is an elevated risk of miscarriages in infertile women and vise versa [5355]. Also, following infertility treatment, a high frequency of miscarriages has been reported [56]. These findings point out that both infertility and miscarriages lie within the spectrum of human reproductive failure that is inclusive of inability to conceive, inability to maintain pregnancy, or post-conception pregnancy loss. Some of the earlier studies have also shown common etiopathogenic pathways underlying these two extreme ends of reproductive failure spectrum [57, 58]. As POI is associated with infertility [5961], thus factors contributing to development of POI may have implication in RM owing to proven links between infertility and the later.

Mutation in several genes has been validated by functional studies to be implicated in POI (for example BMP15, GDF9, FSHR, LHCGR, FOXL2, FIGLA, NR5A1, NOBOX, NANOS3, and STAG3) [51, 6272]. Several mutations in folliculogenesis growth factors like BMP15 and GDF9 gene have been reported in POI women with either primary or secondary amenorrhea [65, 66, 7384]. The influence of level of these factors (GDF9 and BMP15) in the follicular fluid, on the quality of the embryo, has been studied formerly. It was observed that a high mature GDF9 level in follicular fluid was positively correlated with embryo quality [85]. Similarly, role of BMP15 in determining oocyte quality and developmental potential has also been previously recognized with a finding that a high BMP15 level in follicular fluid is associated with best grade embryo morphology [85, 86]. Also, augmented levels of GDF9 and BMP15 mRNA in cumulus granulosa cells are found to correlate with oocyte maturation, fertilization, embryo quality, and pregnancy outcome in humans [87]. All these findings suggest that the intra-ovarian BMP/GDF system is of great importance in regulating a spectrum of ovarian functions from establishment of OR to generation of a competent oocyte for embryo development and thus may have roles in problems of infertility/subfertility and miscarriages both.

Once a high-quality oocyte is generated, the next important primary process required for successful reproduction is the transformation of this terminally differentiated oocyte to a pluripotent embryo after fertilization. Before the massive activation of zygotic genes, the early embryo development solely relies on the maternal transcripts and proteins that have accumulated during the course of folliculogenesis and oogenesis [8891]. The genes encoding these transcripts and proteins are called as maternal effect genes (MEG) and are fundamental for early cleavage events post-fertilization [92, 93]. The maternal effect proteins can interact together to form a large multiprotein complex known as sub-cortical maternal complex (SCMC), which are uniquely expressed in oocytes and in early embryos. Studies conducted on mice model with mutations in genes encoding these maternally provided proteins and multi-component complexes showed impaired early embryonic development and hence leads to RM [94100]. In a recent publication, the authors have identified human SCMC homologous genes (NLRP5, OOEP, TLE6, and KHDC3L) to be specifically expressed in the oocytes of human fetal ovaries and concluded that the human SCMC and its regulators may too have similar central role in early embryonic development. Investigating these oocyte-specific genes can thus provide answer for many unresolved RM cases [101]. In this context, various oocyte-specific transcription factors like FIGLA, NOBOX, SOHLH1, and SOHLH2 have been found to regulate the expression of important MEG like PADI6, KHDC3L, NLRP gene family, Pou5f1 [97, 102109]. The same oocyte-specific transcriptional factors have been identified to have established role in controlling the expression of genes involved follicular development also [105108, 110112]. Furthermore, mutations in genes encoding these transcription factors are found to be associated with POI [52, 62, 68, 113119]. This suggests an interconnected pathway between various facets of reproduction, viz. folliculogenesis and establishment of OR, pathogenic depletion of OR and RM.

Another important ovarian transcription factor is FOXO3 which plays a key role in appropriate maintenance of the ovarian functioning, belongs to the FOXO (Forkhead box O) family of transcription factors, it acts as a key regulator for follicle activation or quiescence [Hopkins et al. 2014]. Constitutive activation of this protein blocks primordial follicle growth and thus induces infertility [120]. Other member of this family, FOXO1a, regulates the cell cycle progression [121]. A number of studies have described potential POI-causing variants both in FOXO3A and FOXO1A [122, 123]. FOXL2, which also belongs to fork head family, is also identified to function as the central transcription factor of the ovary and is essential for follicular maturation and maintenance of ovarian identity [124]. Heterozygous mutations in FOXL2 have been identified in 90% cases of BPES (Blepharophimosis, ptosis, epicanthus inversus syndrome) [125127], an autosomal dominant syndrome with complex eyelid malformations either associated with POI (type I BPES) or not (type II). FOXL2 mutation has also been reported in isolated form of POI [128, 129].

Evidences have proved the role of these FOX factors in regulating the development and differentiation of endometrial cells during pregnancy also. This process is called as endometrial decidulization, and it is indispensable for the placental formation as it helps in maintaining the proper microenvironment for the implantation and growth of the embryo. An impaired decidualization of endometrium disables embryo-maternal recognition and selection upon implantation, which causes RM [130133]. For instance, FOXO1 protein is recognized to have a critical role in regulation of progesterone-dependent endometrial decidulization and protection of the feto-maternal interface against oxidative damage during pregnancy [134137]. Similarly, another forkhead protein implicated in POI, i.e., FOXL2, has been recently shown to be strongly expressed in the uterine tissue of human, mice, and bovine besides its early expression in the ovarian follicles and granulosa cells [138140]. Studies have also shown that FOXL2 controls the expression profile of the endometrial genes and plays a pivotal role in regulating uterus receptivity and embryo implantation [141, 142]. Owing to high level of expressivity and functionality of these FOX proteins in the uterine tissue, in addition to ovaries, speculates that mutation in these genes may have significant implication in RM alongside with their putative role in POI.

Conclusion

In summary, it is understood that the clinical miscarriages result either when a poor quality oocyte develops into poor quality embryo which subsequently fails to implant properly, or when a high-quality embryo gets implanted in a hostile uterine environment which does not support the embryo growth. As there are evidences, the oocyte quality, embryogenesis, and also the uterine microenvironment are governed by various oocyte-specific genes, while most of these genes are also implicated in POI, thus a connecting etiological link between infertility and RM could be thought of. Interrogating the oocyte-specific genes with suspected roles in reproductive biology, in cases of unexplained RM, may open new possibilities in widening our understanding of RM pathophysiology.

Acknowledgments

The author is thankful Council of Science and Industrial Research (CSIR)–New Delhi for providing her fellowship.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Contributor Information

Deepika Delsa Dean, Email: deepikadean.ddd@gmail.com.

Sarita Agarwal, Phone: 91- 522-2494349, Email: saritasgpgi@gmail.com.

Poonam Tripathi, Email: poonamtripathi90@gmail.com.

References

  • 1.Royal College of Obstetricians and Gynaecologists (RCOG). The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage. Green-top Guideline No. 17. Royal College of Obstetricians and Gynaecologists (RCOG), 2011.
  • 2.Coulam CB. Epidemiology of recurrent spontaneous abortion. Am J Reprod Immunol. 1991;26:23–27. doi: 10.1111/j.1600-0897.1991.tb00697.x. [DOI] [PubMed] [Google Scholar]
  • 3.Royal College of Obstetricians and Gynaecologists, Scientific Advisory Committee, Guideline No. 17. The Investigation and treatment of couples with recurrent miscarriage. 2011.
  • 4.Macklon NS, Geraedts JP, Fauser BC. Conception to ongoing pregnancy: the 'black box' of early pregnancy loss. Hum Reprod Update. 2002;8(4):333–343. doi: 10.1093/humupd/8.4.333. [DOI] [PubMed] [Google Scholar]
  • 5.McNamee K, Dawood F, Farquharson R. Recurrent miscarriage and thrombophilia: an update. Curr Opin Obstet Gynecol. 2012;24:229–234. doi: 10.1097/GCO.0b013e32835585dc. [DOI] [PubMed] [Google Scholar]
  • 6.Duckitt K, Qureshi A. Recurrent miscarriage. Clin Evid. 2011;2:1409. [PMC free article] [PubMed] [Google Scholar]
  • 7.American College of Obstetrics and Gynecologists Committee on Practice Bulletins: ACOG Practice Bulletin. Paper 40. Obstet Gynecol 2011.
  • 8.Cohn DM, Goddijn M, Middeldorp S, et al. Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost. 2010;8:2208–2213. doi: 10.1111/j.1538-7836.2010.04015.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Patel BG, Lessey BA. Clinical assessment and management of the endometrium in recurrent early pregnancy loss. Semin Reprod Med. 2011;29:491–506. doi: 10.1055/s-0031-1293203. [DOI] [PubMed] [Google Scholar]
  • 10.Management of Recurrent Early Pregnancy Loss. Washington, DC: The American College of Obstetricians and Gynecologists; 2001. The American College of Obstetricians and Gynecologists. (ACOG Practice Bulletin No. 24).
  • 11.Ali O, Hakimi I, Chanana A, et al. Grossesse sur utérus cloisonné menée à terme: à propos d’un cas avec revue de la literature. The Pan African Medical Journal. 2015;22:219. doi: 10.11604/pamj.2015.22.219.7790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Pluchino N, Drakopoulos P, Wenger JM, Petignat P, Streuli I, Genazzani AR. Hormonal causes of recurrent pregnancy loss (RPL) Hormones (Athens) 2014;13(3):314–322. doi: 10.14310/horm.2002.1505. [DOI] [PubMed] [Google Scholar]
  • 13.Practice Committee of the American Society for Reproductive Medicine Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012;98(5):1103–1111. doi: 10.1016/j.fertnstert.2012.06.048. [DOI] [PubMed] [Google Scholar]
  • 14.Jovanovic L, Knopp H, Kim H, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancies: evidence for a protective adaptation in diabetes. Diabetes Care. 2005;28(5):1113–1117. doi: 10.2337/diacare.28.5.1113. [DOI] [PubMed] [Google Scholar]
  • 15.Cleary-Goldman J, Malone FD, Lambert-Messerlian G, Sullivan L, Canick J, Porter TF, Luthy D, Gross S, Bianchi DW, D’Alton ME. Maternal thyroid hypofunction and pregnancy outcome. Obstet Gynecol. 2008;112(1):85–92. doi: 10.1097/AOG.0b013e3181788dd7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Sarkar D. Recurrent pregnancy loss in patients with thyroid dysfunction. Indian Journal of Endocrinology and Metabolism. 2012;16(2):S350–S351. doi: 10.4103/2230-8210.104088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Shah D, Nagarajan N. Luteal insufficiency in first trimester. Indian Journal of Endocrinology and Metabolism. 2013;17(1):44–49. doi: 10.4103/2230-8210.107834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Laurino MY, Bennett RL, Saraiya DS, Baumeister L, Doyle DL, Leppig K, Pettersen B, Resta R, Shields L, Uhrich S, Varga EA, Raskind WH. Genetic evaluation and counseling of couples with recurrent miscarriage: recommendations of the National Society of genetic counselors. J Genet Couns. 2005;14(3):165–181. doi: 10.1007/s10897-005-3241-5. [DOI] [PubMed] [Google Scholar]
  • 19.Stephenson MD, Sierra S. Reproductive outcomes in recurrent pregnancy loss associated with a parental carrier of a structural chromosome rearrangement. Hum Reprod. 2006;21(4):1076–1082. doi: 10.1093/humrep/dei417. [DOI] [PubMed] [Google Scholar]
  • 20.Carp H, Guetta E, Dorf H, Soriano D, Barkai G, Schiff E. Embryonic karyotype in recurrent miscarriage with parental karyotypic aberrations. Fertil Steril. 2006;85(2):446–450. doi: 10.1016/j.fertnstert.2005.07.1305. [DOI] [PubMed] [Google Scholar]
  • 21.Benedetto C, Tibaldi C, Marozio L, Marini S, Masuelli G, Pelissetto S, Sozzani P, Latino MA. Cervicovaginal infections during pregnancy: epidemiological and microbiological aspects. J Matern Fetal Neonatal Med. 2004;16(2):9–12. doi: 10.1080/14767050410001727107. [DOI] [PubMed] [Google Scholar]
  • 22.Srinivas SK, Ma Y, Sammel MD, Chou D, McGrath C, Parry S, Elovitz MA. Placental inflammation and viral infection are implicated in second trimester pregnancy loss. Am J Obstet Gynecol. 2006;195:797–802. doi: 10.1016/j.ajog.2006.05.049. [DOI] [PubMed] [Google Scholar]
  • 23.Katz-Jaffe MG, Surrey ES, Minjarez DA, Gustofson RL, Stevens JM, Schoolcraft WB.
  • 24.Association of abnormal ovarian reserve parameters with a higher incidence of aneuploid blastocysts. Obstet Gynecol. 2013 ; 121(1):71–7. [DOI] [PubMed]
  • 25.Matthews TJ, Hamilton BE. Delayed childbearing: more women are having their first child later in life. NCHS Data Brief. 2009;21:1–8. [PubMed] [Google Scholar]
  • 26.Nybo Anderson AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320:1708–1712. doi: 10.1136/bmj.320.7251.1708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Hassold T, Hall H, Hunt P. The origin of human aneuploidy: where we have been, where we are going. Hum Mol Genet. 2007;16:R203–R208. doi: 10.1093/hmg/ddm243. [DOI] [PubMed] [Google Scholar]
  • 28.Nagaoka SI, Hassold TJ, Hunt PA. Human aneuploidy: mechanisms and new insights into an age-old problem. Nat Rev Genet. 2012;13:493–504. doi: 10.1038/nrg3245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Quenby S, Vince G, Farquharson R, Aplin J. OPINION Recurrent miscarriage: A defect in nature's quality control? Hum Reprod. Aug. 2002;17(8):1959–1963. doi: 10.1093/humrep/17.8.1959. [DOI] [PubMed] [Google Scholar]
  • 30.Choi TY, Lee HM, Park WK, Jeong SY, Moon HS. Spontaneous abortion and recurrent miscarriage: a comparison of cytogenetic diagnosis in 250 cases. Obstet Gynecol Sci. 2014;57:518–525. doi: 10.5468/ogs.2014.57.6.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Kwinecka-Dmitriew B, Zakrzewska M, Latos-Bieleńska A, Skrzypczak J. Frequency of chromosomal aberrations in material from abortions. Ginekol Pol. 2010;81(12):896–901. [PubMed] [Google Scholar]
  • 32.Wang YA, Farquhar C, Sullivan EA. Donor age is a major determinant of success of oocyte donation/recipient programme. Hum Reprod. 2012;27(1):118–125. doi: 10.1093/humrep/der359. [DOI] [PubMed] [Google Scholar]
  • 33.Sauer MV, Paulson RJ, Lobo RA. Pregnancy after age 50: application of oocyte donation to women after natural menopause. Lancet. 1993;341:321–323. doi: 10.1016/0140-6736(93)90132-z. [DOI] [PubMed] [Google Scholar]
  • 34.Sauer MV, Paulson RJ, Lobo RA. Pregnancy in women 50 or more years of age: outcomes of 22 consecutively established pregnancies from oocyte donation. Fertil Steril. 1995;64:111–115. [PubMed] [Google Scholar]
  • 35.Antinori S, Versaci C, Gholami GH, Panci C, Caffa B. Oocyte donation in menopausal women. Hum Reprod. 1993;8:1487–1490. doi: 10.1093/oxfordjournals.humrep.a138284. [DOI] [PubMed] [Google Scholar]
  • 36.Check JH, Nowroozi K, Barnea ER, Shaw KJ, Sauer MV. Successful delivery after age 50: a report of two cases as a result of oocyte donation. Obstet Gynecol. 1993;81:835–836. [PubMed] [Google Scholar]
  • 37.Sills ES, Anthony MM, Walsh PH. Ovarian reserve screening in infertility: practical applications and theoretical directions for research. Eur J Obstet Gynecol Reprod Biol. 2009;146(1):30–36. doi: 10.1016/j.ejogrb.2009.05.008. [DOI] [PubMed] [Google Scholar]
  • 38.May-Panloup P, Ferré-L'Hôtellier V, Morinière C, Marcaillou C, Lemerle S, Malinge MC, Coutolleau A, Lucas N, Reynier P, Descamps P, Guardiola P. Molecular characterization of corona radiata cells from patients with diminished ovarian reserve using microarray and microfluidic-based gene expression profiling. Hum Reprod. 2012;27(3):829–843. doi: 10.1093/humrep/der431. [DOI] [PubMed] [Google Scholar]
  • 39.El Toukhy T, Khalaf Y, Hart R, Taylor A. Braude P; young age does not protect against the adverse effects of reduced ovarian reserve—an eight year study. Hum Reprod. 2002;17(6):1519–1524. doi: 10.1093/humrep/17.6.1519. [DOI] [PubMed] [Google Scholar]
  • 40.Maroulis GB. Effect of aging on fertility and pregnancy. Semin Reprod Endocrinol. 1991;9:165–175. [Google Scholar]
  • 41.Volarcik K, Sheean L, Goldfarb J, Woods L, Abdul-Karim FW, Hunt P. The meiotic competence of in-vitro matured human oocytes is influenced by donor age: evidence that folliculogenesis is compromised in the reproductively aged ovary. Hum Reprod. 1998;13:154–160. doi: 10.1093/humrep/13.1.154. [DOI] [PubMed] [Google Scholar]
  • 42.Delhanty JD. Mechanisms of aneuploidy induction in human oogenesis and early embryogenesis. Cytogenet Genome Res. 2005;111:237–244. doi: 10.1159/000086894. [DOI] [PubMed] [Google Scholar]
  • 43.Pellestor F, Andre’ OB, Anahory T, Hamamah S. The occurrence of aneuploidy in human: lessons from the cytogenetic studies of human oocytes. Eur J Med Genet. 2006;49:103–116. doi: 10.1016/j.ejmg.2005.08.001. [DOI] [PubMed] [Google Scholar]
  • 44.Tsutsumi M, Fujiwara R, Nishizawa H, Ito M, Kogo H, Inagaki H, Ohye T, Kato T, Fujii T, Kurahashi H. Agerelated decrease of meiotic cohesins in human oocytes. PLoS One. 2014;9:e96710. doi: 10.1371/journal.pone.0096710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Atasever M, Soyman Z, Demirel E, Gencdal S, Kelekci S. Diminished ovarian reserve: is it a neglected cause in the assessment of recurrent miscarriage? A cohort study. Fertil Steril. 2016;105(5):1236–1240. doi: 10.1016/j.fertnstert.2016.01.001. [DOI] [PubMed] [Google Scholar]
  • 46.Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR, Klein NA. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum Reprod. 2008;23:699–708. doi: 10.1093/humrep/dem408. [DOI] [PubMed] [Google Scholar]
  • 47.Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5(1):e8772. doi: 10.1371/journal.pone.0008772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Oktem O, Urman B. Understanding follicle growth in vivo. Hum Reprod. 2010;25(12):2944–2954. doi: 10.1093/humrep/deq275. [DOI] [PubMed] [Google Scholar]
  • 49.Ottolenghi C, Uda M, Hamatani T, Crisponi L, Garcia JE, KoM PG, Sforza C, Schlessinger D, Forabosco A. Aging of oocyte, ovary, and human reproduction. Ann N Y Acad Sci. 2004;1034:117–131. doi: 10.1196/annals.1335.015. [DOI] [PubMed] [Google Scholar]
  • 50.Broekmans FJ, Knauff EA, te Velde ER, Macklon NS, Fauser BC. Female reproductive ageing: current knowledge and future trends. Trends Endocrinol Metab. 2007;18:58–65. doi: 10.1016/j.tem.2007.01.004. [DOI] [PubMed] [Google Scholar]
  • 51.Chapman C, Cree L, Shelling AN. The genetics of premature ovarian failure: current perspectives. Int J Womens Health. 2015;7:799–810. doi: 10.2147/IJWH.S64024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Qin Y, Jiao X, Simpson JL. Chen ZJ genetics of primary ovarian insufficiency: new developments and opportunities. Hum Reprod Update. 2015;21(6):787–808. doi: 10.1093/humupd/dmv036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Hakim RB, Gray RH, Zacur H. Infertility and early pregnancy loss. Obstet Gynecol. 1995;172(5):1510–1517. doi: 10.1016/0002-9378(95)90489-1. [DOI] [PubMed] [Google Scholar]
  • 54.Coulam CB. Association between infertility and spontaneous abortion. Am J Reprod Immunol. 1992;27(3–4):128–129. doi: 10.1111/j.1600-0897.1992.tb00739.x. [DOI] [PubMed] [Google Scholar]
  • 55.Molo MW, Kelly M, Balos R, Mullaney K, Radwanska E. Incidence of fetal loss in infertility patients after detection of fetal heart activity with early transvaginal ultrasound. J Reprod Med. 1993;38(10):804–806. [PubMed] [Google Scholar]
  • 56.Liu HC, Rosenwaks Z. Early pregnancy wastage in IVF (in vitro fertilization) patients. J In Vitro Fert Embryo Transf. 1991;8(2):65–72. doi: 10.1007/BF01138657. [DOI] [PubMed] [Google Scholar]
  • 57.Cocksedge KA, Li TC, Saravelos SH, Metwally MA. Reappraisal of the role of polycystic ovary syndrome in recurrent miscarriage. Reprod BioMed Online. 2008;17(1):151–160. doi: 10.1016/s1472-6483(10)60304-5. [DOI] [PubMed] [Google Scholar]
  • 58.Trogstad L, Magnus P, Moffett A, Stoltenberg C. The effect of recurrent miscarriage and infertility on the risk of pre-eclampsia. BJOG. 2009;116(1):108–113. doi: 10.1111/j.1471-0528.2008.01978.x. [DOI] [PubMed] [Google Scholar]
  • 59.Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67:604–606. [PubMed] [Google Scholar]
  • 60.Torrealday S, Kodaman P, Pal L. Premature Ovarian Insufficiency - an update on recent advances in understanding and management. F1000Research. 2017;6:2069. doi: 10.12688/f1000research.11948.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Sato Y, Kawamura N, Kawamura K. Infertility Treatment in Primary Ovarian Insufficiency: Fertility Preservation and In Vitro Activation. J Gynecol Women’s Health. 2017; 7(1): JGWH.MS.ID.555704.
  • 62.Qin Y, Choi Y, Zhao H, Simpson JL, Chen ZJ, Rajkovic A. NOBOX homeobox mutation causes premature ovarian failure. Am J Hum Genet. 2007;81(3):576–581. doi: 10.1086/519496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Lourenço D, Brauner R, Lin L, De Perdigo A, Weryha G, et al. Mutations in NR5A1 associated with ovarian insufficiency. N Engl J Med. 2009;360(12):1200–1210. doi: 10.1056/NEJMoa0806228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Rah H, Jeon YJ, Ko JJ, Kim JH, Kim YR, Cha SH, Choi Y, Lee WS, Kim NK. Association of inhibin α gene promoter polymorphisms with risk of idiopathic primary ovarian insufficiency in Korean women. Maturitas. 2014;77(2):163–167. doi: 10.1016/j.maturitas.2013.10.015. [DOI] [PubMed] [Google Scholar]
  • 65.Chand AL, Ponnampalam AP, Harris SE, et al. Mutational analysis of BMP15 and GDF9 as candidate genes for premature ovarian failure. Fertil Steril. 2006;86(4):1009–1012. doi: 10.1016/j.fertnstert.2006.02.107. [DOI] [PubMed] [Google Scholar]
  • 66.Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein- 15 (BMP15) gene. Am J Hum Genet. 2004;75(1):106–111. doi: 10.1086/422103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Santos MG, Machado AZ, Martins CN, et al. Homozygous Inactivating Mutation in NANOS3 in Two Sisters with Primary Ovarian Insufficiency. Biomed Res Int. 2014;2014(787465):8. doi: 10.1155/2014/787465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Wu X, Wang B, Dong Z, Zhou S, Liu Z, Shi G, Cao Y, Xu Y. A NANOS3 mutation linked to protein degradation causes premature ovarian insufficiency. Cell Death Dis. 2013;4:e825. doi: 10.1038/cddis.2013.368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Tucker EJ, Grover SR, Bachelot A, Touraine P, Sinclair AH. Premature ovarian insufficiency: new perspectives on genetic cause and phenotypic Spectrum. Endocr Rev. 2016;37(6):609–635. doi: 10.1210/er.2016-1047. [DOI] [PubMed] [Google Scholar]
  • 70.Fonseca DJ, Patiño LC, Suárez YC, et al. Next generation sequencing in women affected by nonsyndromic premature ovarian failure displays new potential causative genes and mutations. Fertil Steril. 2015;104(1):154–162. doi: 10.1016/j.fertnstert.2015.04.016. [DOI] [PubMed] [Google Scholar]
  • 71.Aittomäki K, Lucena JL, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell. 1995;82(6):959–968. doi: 10.1016/0092-8674(95)90275-9. [DOI] [PubMed] [Google Scholar]
  • 72.Caburet S, Arboleda VA, Llano E, Overbeek PA, Barbero JL, Oka K, Harrison W, Vaiman D, Ben-Neriah Z, García-Tuñón I, Fellous M, Pendás AM, Veitia RA, Vilain E. Mutant cohesin in premature ovarian failure. N Engl J Med. 2014;370(10):943–949. doi: 10.1056/NEJMoa1309635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Takebayashi K, Takakura K, Wang H, Kimura F, et al. Mutation analysis of the growth differentiation factor-9 and −9B genes in patients with premature ovarian failure and polycystic ovary syndrome. Fertil Steril. 2000;74:976–979. doi: 10.1016/s0015-0282(00)01539-9. [DOI] [PubMed] [Google Scholar]
  • 74.Di Pasquale E, Rossetti R, Marozzi A, Bodega B, et al. Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J Clin Endocrinol Metab. 2006;91(5):1976–1979. doi: 10.1210/jc.2005-2650. [DOI] [PubMed] [Google Scholar]
  • 75.Dixit H, Rao LK, Padmalatha V, Kanakavalli M, Deenadayal M, Gupta N, Chakravarty B, Singh L. Mutational screening of the coding region of growth differentiation factor 9 gene in Indian women with ovarian failure. Menopause. 2005;12(6):749–754. doi: 10.1097/01.gme.0000184424.96437.7a. [DOI] [PubMed] [Google Scholar]
  • 76.Persani L, Rossetti R, Cacciatore C. Genes involved in human premature ovarian failure. J Mol Endocrinol. 2010;45(5):257–279. doi: 10.1677/JME-10-0070. [DOI] [PubMed] [Google Scholar]
  • 77.Tiotiu D, Alvaro Mercadal B, Imbert R, Verbist J, Demeestere I, de Leener A, Englert Y, Vassart G, Costagliola S, Delbaere A. Variants of the BMP15 gene in a cohort of patients with premature ovarian failure. Hum Reprod. 2010;25(6):1581–1587. doi: 10.1093/humrep/deq073. [DOI] [PubMed] [Google Scholar]
  • 78.Auclair S, Rossetti R, Meslin C, Monestier O, di Pasquale E, Pascal G, Persani L, Fabre S. Positive selection in bone morphogenetic protein 15 targets a natural mutation associated with primary ovarian insufficiency in human. PLoS One. 2013;8(10):e78199. doi: 10.1371/journal.pone.0078199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Ferrarini E, Russo L, Fruzzetti F, Agretti P, De Marco G, et al. Clinical characteristics and genetic analysis in women with premature ovarian insufficiency. Maturitas. 2013;74(1):61–67. doi: 10.1016/j.maturitas.2012.09.017. [DOI] [PubMed] [Google Scholar]
  • 80.Dixit H, Rao LK, Padmalatha VV, Kanakavalli M, et al. Missense mutations in the BMP15 gene are associated with ovarian failure. Hum Genet. 2006;119(4):408–415. doi: 10.1007/s00439-006-0150-0. [DOI] [PubMed] [Google Scholar]
  • 81.Laissue P, Christin-Maitre S, Touraine P, Kuttenn F, Ritvos O, Aittomaki K, Bourcigaux N, Jacquesson L, Bouchard P, Frydman R, Dewailly D, Reyss AĆ, Jeffery L, Bachelot A, Massin N, Fellous M, Veitia RA. Mutations and sequence variants in GDF9 and BMP15 in patients with premature ovarian failure. Eur J Endocrinol. 2006;154(5):739–744. doi: 10.1530/eje.1.02135. [DOI] [PubMed] [Google Scholar]
  • 82.Kovanci E, Rohozinski J, Simpson JL, Heard MJ, et al. Growth differentiating factor-9 mutations may be associated with premature ovarian failure. Fertil Steril. 2007;87(1):143–146. doi: 10.1016/j.fertnstert.2006.05.079. [DOI] [PubMed] [Google Scholar]
  • 83.Wang TT, Ke ZH, Song Y, Chen LT, Chen XJ, Feng C, Zhang D, Zhang RJ, Wu YT, Zhang Y, Sheng JZ, Huang HF. Identification of a mutation in GDF9 as a novel cause of diminished ovarian reserve in young women. Hum Reprod. 2013;28(9):2473–2481. doi: 10.1093/humrep/det291. [DOI] [PubMed] [Google Scholar]
  • 84.Simpson CM, Robertson DM, Al-Musawi SL, Heath DA, et al. Aberrant GDF9 expression and activation are associated with common human ovarian disorders. J Clin Endocrinol Metab. 2014;99(4):E615–E624. doi: 10.1210/jc.2013-3949. [DOI] [PubMed] [Google Scholar]
  • 85.Gode F, Gulekli B, Dogan E, Korhan P, Dogan S, Bige O, Cimrin D, Atabey N. Influence of follicular fluid GDF9 and BMP15 on embryo quality. Fertil Steril. 2011;95(7):2274–2278. doi: 10.1016/j.fertnstert.2011.03.045. [DOI] [PubMed] [Google Scholar]
  • 86.Wu Y-T, Tang L, Cai J, Lu X-E, Xu J, Zhu X-M, Luo Q, Huang H-F. High bone morphogenetic protein-15 level in follicular fluid is associated with high quality oocyte and subsequent embryonic development. Hum Reprod. 2007;22(6):1526–1531. doi: 10.1093/humrep/dem029. [DOI] [PubMed] [Google Scholar]
  • 87.Li Y, Li RQ, Ou SB, Zhang NF, Ren L, Wei LN, Zhang QX, Yang DZ. Increased GDF9 and BMP15 mRNA levels in cumulus granulosa cells correlate with oocyte maturation, fertilization, and embryo quality in humans. Reprod Biol Endocrinol. 2014;12:81. doi: 10.1186/1477-7827-12-81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Lee MT, Bonneau AR, Giraldez AJ. Zygotic genome activation during the maternal-to-zygotic transition. Annu Rev Cell Dev Biol. 2014;30:581–613. doi: 10.1146/annurev-cellbio-100913-013027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Tadros W, Lipshitz HD. The maternal-to-zygotic transition: a play in two acts. Development. 2009;136:3033–3042. doi: 10.1242/dev.033183. [DOI] [PubMed] [Google Scholar]
  • 90.Langley AR, Smith JC, Stemple DL, Harvey SA. New insights into the maternal to zygotic transition. Development. 2014;141:3834–3841. doi: 10.1242/dev.102368. [DOI] [PubMed] [Google Scholar]
  • 91.Lu X, Gao Z, Qin D, Li L. A maternal functional module in the mammalian oocyte-to-embryo transition. Trends Mol Med. 2017;23(11):1014–1023. doi: 10.1016/j.molmed.2017.09.004. [DOI] [PubMed] [Google Scholar]
  • 92.Matzuk MM, Burns KH, Viveiros MM, Eppig JJ. Intercellular communication in the mammalian ovary: oocytes carry the conversation. Science. 2002;296:2178–2180. doi: 10.1126/science.1071965. [DOI] [PubMed] [Google Scholar]
  • 93.Bettegowda A, Lee KB, Smith GW. Cytoplasmic and nuclear determinants of the maternal-to-embryonic transition. Reprod Fertil Dev. 2008;20(1):45–53. doi: 10.1071/rd07156. [DOI] [PubMed] [Google Scholar]
  • 94.Flach G, Johnson MH, Braude PR, Taylor RA, Bolton VN. The transition from maternal to embryonic control in the 2-cell mouse embryo. EMBO J. 1982;1:681–686. doi: 10.1002/j.1460-2075.1982.tb01230.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Li L, Zheng P, Dean J. Maternal control of early mouse development. Development. 2010;137(6):859–870. doi: 10.1242/dev.039487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Huang JY, Su M, Lin SH, Kuo PL. A genetic association study of NLRP2 and NLRP7genes in idiopathic recurrent miscarriage. Hum Reprod. 2013;28(4):1127–1134. doi: 10.1093/humrep/det001. [DOI] [PubMed] [Google Scholar]
  • 97.Qian J, Nguyen NMP, Rezaei M, Huang B, Tao Y, Zhang XF, Cheng Q, Yang HJ, Asangla A, Majewski J, Slim R. Biallelic PADI6 variants linking infertility, miscarriages, and hydatidiform moles. Eur J Hum Genet. 2018;26(7):1007–1013. doi: 10.1038/s41431-018-0141-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Fogarty NME, McCarthy A, Snijders KE, Powell BE, Kubikova N, Blakeley P, Lea R, Elder K, Wamaitha SE, Kim D, Maciulyte V, Kleinjung J, Kim JS, Wells D, Vallier L, Bertero A, Turner JMA, Niakan KK. Genome editing reveals a role for OCT4 in human embryogenesis. Nature. 2017;550(7674):67–73. doi: 10.1038/nature24033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Zhang P, Dixon M, Zucchelli M, Hambiliki F, Levkov L, Hovatta O, Kere J. Expression analysis of the NLRP gene family suggests a role in human preimplantation development. PLoS One. 2008;3(7):e2755. doi: 10.1371/journal.pone.0002755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Li L, Baibakov B, Dean J. A subcortical maternal complex essential for preimplantation mouse embryogenesis. Dev Cell. 2008;15(3):416–425. doi: 10.1016/j.devcel.2008.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Zhu K, Yan L, Zhang X, Lu X, Wang T, Yan J, Liu X, Qiao J, Li L. Identification of a human subcortical maternal complex. Mol Hum Reprod. 2015;21(4):320–329. doi: 10.1093/molehr/gau116. [DOI] [PubMed] [Google Scholar]
  • 102.Wu G, Schöler HR. Role of Oct4 in the early embryo development. Cell Regeneration. 2014;3(1):7. doi: 10.1186/2045-9769-3-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Joshi S, Davies H, Sims LP, Levy SE, Dean J. Ovarian gene expression in the absence of FIGLA, an oocyte-specific transcription factor. BMC Dev Biol. 2007;7:67. doi: 10.1186/1471-213X-7-67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Choi Y, Qin Y, Berger M, Ballow D, et al. Microarray analyses of newborn mouse ovaries lacking Nobox. Biol Reprod. 2007;77(2):312–319. doi: 10.1095/biolreprod.107.060459. [DOI] [PubMed] [Google Scholar]
  • 105.Choi Y, Rajkovic A. Characterization of NOBOX DNA binding specificity and its regulation of Gdf9 and Pou5f1 promoters. J Biol Chem. 2006;281(47):35747–35756. doi: 10.1074/jbc.M604008200. [DOI] [PubMed] [Google Scholar]
  • 106.Tsuda M, Sasaoka Y, Kiso M, Abe K, Haraguchi S, Kobayashi S, Saga Y. Conserved role of nanos proteins in germ cell development. Science. 2003;301:1239–1241. doi: 10.1126/science.1085222. [DOI] [PubMed] [Google Scholar]
  • 107.Stephanie A. Pangas, Aleksandar Rajkovic; transcriptional regulation of early oogenesis: in search of masters. Hum Reprod Update. 2006;12(1):65–76. doi: 10.1093/humupd/dmi033. [DOI] [PubMed] [Google Scholar]
  • 108.Rajkovic A, Pangas SA, Ballow D, Suzumori N, Matzuk MM. NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression. Science. 2004;305:1157–1159. doi: 10.1126/science.1099755. [DOI] [PubMed] [Google Scholar]
  • 109.Tripurani SK, Lee K-B, Wang L, Wee G, Smith GW, Lee YS, Latham KE, Yao J. A novel functional role for the oocyte-specific transcription factor newborn ovary Homeobox (NOBOX) during early embryonic development in cattle. Endocrinology. 2011;152(3):1013–1023. doi: 10.1210/en.2010-1134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Lim E-J, Choi Y. Transcription factors in the maintenance and survival of primordial follicles. Clinical and Experimental Reproductive Medicine. 2012;39(4):127–131. doi: 10.5653/cerm.2012.39.4.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Shin YH, Ren Y, Suzuki H, Golnoski KJ, Ahn HW, Mico V, Rajkovic A. Transcription factors SOHLH1 and SOHLH2 coordinate oocyte differentiation without affecting meiosis I. J Clin Invest. 2017;127(6):2106–2117. doi: 10.1172/JCI90281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Pangas SA, Choi Y, Ballow DJ, Zhao Y, Westphal H, Matzuk MM, Rajkovic A. Oogenesis requires germ cell-specific transcriptional regulators Sohlh1 and Lhx8. Proc Natl Acad Sci U S A. 2006;103(21):8090–8095. doi: 10.1073/pnas.0601083103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Bouilly J, Beau I, Barraud S, Bernard V, Azibi K, Fagart J, Fèvre A, Todeschini AL, Veitia RA, Beldjord C, Delemer B, Dodé C, Young J, Binart N. Identification of multiple gene mutations accounts for a new genetic architecture of primary ovarian insufficiency. J Clin Endocrinol Metab. 2016;101(12):4541–4550. doi: 10.1210/jc.2016-2152. [DOI] [PubMed] [Google Scholar]
  • 114.Zhao S, Li G, Dalgleish R, Vujovic S, Jiao X, Li J, Simpson JL, et al. Transcription factor SOHLH1 potentially associated with primary ovarian insufficiency. Fertil Steril. 2015;103(2):548–553. doi: 10.1016/j.fertnstert.2014.11.011. [DOI] [PubMed] [Google Scholar]
  • 115.Qin Y, Jiao X, Dalgleish R, Vujovic S, Li J, et al. Novel variants in the SOHLH2 gene are implicated in human premature ovarian failure. Fertil Steril. 2014;101(4):1104–1109. doi: 10.1016/j.fertnstert.2014.01.001. [DOI] [PubMed] [Google Scholar]
  • 116.Ferrari I, Bouilly J, Beau I, Guizzardi F, Ferlin A, Pollazzon M, Salerno M, Binart N, Persani L, Rossetti R. Impaired protein stability and nuclear localization of NOBOX variants associated with premature ovarian insufficiency. Hum Mol Genet. 2016;25(23):5223–5233. doi: 10.1093/hmg/ddw342. [DOI] [PubMed] [Google Scholar]
  • 117.Li L, Wang B, Zhang W, Chen B, Luo M, Wang J, Wang X, Cao Y, Kee K. A homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency. Hum Reprod. 2017;32(1):248–255. doi: 10.1093/humrep/dew271. [DOI] [PubMed] [Google Scholar]
  • 118.Jiao X, Qin Y, Li G et al. Novel NR5A1 Missense Mutation in Premature Ovarian Failure: Detection in Han Chinese Indicates Causation in Different Ethnic Groups. Sun Q-Y, ed. PLoS ONE. 2013; 8(9):e74759. [DOI] [PMC free article] [PubMed]
  • 119.Tosh D, Rani HS, Murty US, Deenadayal A, Grover P. Mutational analysis of the FIGLA gene in women with idiopathic premature ovarian failure. Menopause. 2015;22(5):520–526. doi: 10.1097/GME.0000000000000340. [DOI] [PubMed] [Google Scholar]
  • 120.Liu L, Rajareddy S, Reddy P, du C, Jagarlamudi K, Shen Y, Gunnarsson D, Selstam G, Boman K, Liu K. Infertility caused by retardation of follicular development in mice with oocyte-specific expression of Foxo3a. Development. 2007;134:199–209. doi: 10.1242/dev.02667. [DOI] [PubMed] [Google Scholar]
  • 121.Cunningham MA, Zhu Q, Hammond JM. FoxO1a can alter cell cycle progression by regulating the nuclear localization of p27kip in granulosa cells. Mol Endocrinol. 2004;18:1756–1767. doi: 10.1210/me.2004-0071. [DOI] [PubMed] [Google Scholar]
  • 122.Vinci G, Christin-Maitre S, Pasquier M, et al. FOXO3a variants in patients with premature ovarian failure. Clin Endocrinol. 2008;68:495–497. doi: 10.1111/j.1365-2265.2007.03052.x. [DOI] [PubMed] [Google Scholar]
  • 123.Watkins WJ, Umbers AJ, Woad KJ, Harris SE, et al. Mutational screening of FOXO3A and FOXO1A in women with premature ovarian failure. Fertil Steril. 2006;5:1518–1521. doi: 10.1016/j.fertnstert.2006.03.054. [DOI] [PubMed] [Google Scholar]
  • 124.Pisarska MD, Bae J, Klein C, Aaron J, Hsueh W. Forkhead L2 Is Expressed in the Ovary and Represses the Promoter Activity of the Steroidogenic Acute Regulatory Gene. Endocrinology. 2004;145(7):3424–3433. doi: 10.1210/en.2003-1141. [DOI] [PubMed] [Google Scholar]
  • 125.Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, Bisceglia L, Zelante L, Nagaraja R, Porcu S, Serafina Ristaldi M, Marzella R, Rocchi M, Nicolino M, Lienhardt-Roussie A, Nivelon A, Verloes A, Schlessinger D, Gasparini P, Bonneau D, Cao A, Pilia G. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet. 2001;27:159–166. doi: 10.1038/84781. [DOI] [PubMed] [Google Scholar]
  • 126.Méduri G, Bachelot A, Duflos C, et al. FOXL2 mutations lead to different ovarian phenotypes in BPES patients: case report. Hum Reprod. 2010;25:235–243. doi: 10.1093/humrep/dep355. [DOI] [PubMed] [Google Scholar]
  • 127.Nallathambi J, Moumné L, De Baere E, et al. A novel polyalanine expansion in FOXL2: the first evidence for a recessive form of the blepharophimosis syndrome (BPES) associated with ovarian dysfunction. Hum Genet. 2007;121:107–112. doi: 10.1007/s00439-006-0276-0. [DOI] [PubMed] [Google Scholar]
  • 128.Harris SE, Chand AL, Winship IM, Gersak K, Aittomäki K, Shelling AN. Identification of novel mutations in FOXL2 associated with premature ovarian failure. Mol Hum Reprod. 2002;8(8):729–733. doi: 10.1093/molehr/8.8.729. [DOI] [PubMed] [Google Scholar]
  • 129.Laissue P, Lakhal B, Benayoun BA, Dipietromaria A, Braham R, Elghezal H, Philibert P, Saad A, Sultan C, Fellous M, Veitia RA. Functional evidence implicating FOXL2 in non-syndromic premature ovarian failure and in the regulation of the transcription factor OSR2. J Med Genet. 2009;46:455–457. doi: 10.1136/jmg.2008.065086. [DOI] [PubMed] [Google Scholar]
  • 130.Salker M, Teklenburg G, Molokhia M et al. Natural Selection of Human Embryos: Impaired Decidualization of Endometrium Disables Embryo-Maternal Interactions and Causes Recurrent Pregnancy Loss. Vitzthum VJ, ed. PLoS ONE. 2010; 5(4):e10287. [DOI] [PMC free article] [PubMed]
  • 131.Salker MS, Christian M, Steel JH, Nautiyal J, Lavery S, Trew G, Webster Z, al-Sabbagh M, Puchchakayala G, Föller M, Landles C, Sharkey AM, Quenby S, Aplin JD, Regan L, Lang F, Brosens JJ. Deregulation of the serum- and glucocorticoid-inducible kinase SGK1 in the endometrium causes reproductive failure. Nat Med. 2011;17:1509–1513. doi: 10.1038/nm.2498. [DOI] [PubMed] [Google Scholar]
  • 132.Salker MS, Nautiyal J, Steel JH, Webster Z, Šućurović S, Nicou M, Singh Y, Lucas ES, Murakami K, Chan YW, James S, Abdallah Y, Christian M, Croy BA, Mulac-Jericevic B, Quenby S, Brosens JJ. Disordered IL-33/ST2 activation in decidualizing stromal cells prolongs uterine receptivity in women with recurrent pregnancy. PLoS One. 2012;7(12):e52252. doi: 10.1371/journal.pone.0052252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Lucas ES, Dyer NP, Murakami K, Hou Lee Y, Chan YW, Grimaldi G, Muter J, Brighton PJ, Moore JD, Patel G, Chan JKY, Takeda S, Lam EWF, Quenby S, Ott S, Brosens JJ. Loss of endometrial plasticity in recurrent pregnancy loss. Stem Cells. 2016;34:346–356. doi: 10.1002/stem.2222. [DOI] [PubMed] [Google Scholar]
  • 134.Christian M, Zhang X, Schneider-Merck T, Unterman TG, Gellersen B, White JO, Brosens JJ. Cyclic AMP-induced forkhead transcription factor, FKHR, cooperates with CCAAT/enhancer-binding protein β in differentiating human endometrial stromal cells. J Biol Chem. 2002;277:20825–20832. doi: 10.1074/jbc.M201018200. [DOI] [PubMed] [Google Scholar]
  • 135.Labied S, Kajihara T, Madureira PA, Fusi L, Jones MC, Higham JM, Varshochi R, Francis JM, Zoumpoulidou G, Essafi A, Fernandez de Mattos S, Lam EWF, Brosens JJ. Progestins regulate the expression and activity of the Forkhead transcription factor FOXO1 in differentiating human endometrium. Mol Endocrinol. 2006;20(1):35–44. doi: 10.1210/me.2005-0275. [DOI] [PubMed] [Google Scholar]
  • 136.Kajihara T, Jones M, Fusi L, Takano M, Feroze-Zaidi F, Pirianov G, Mehmet H, Ishihara O, Higham JM, Lam EWF, Brosens JJ. Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. Mol Endocrinol. 2006;20(10):2444–2455. doi: 10.1210/me.2006-0118. [DOI] [PubMed] [Google Scholar]
  • 137.Kajihara T, Brosens JJ, Ishihara O. The role of FOXO1 in the decidual transformation of the endometrium and early pregnancy. Med Mol Morphol. 2013;46(2):61–68. doi: 10.1007/s00795-013-0018-z. [DOI] [PubMed] [Google Scholar]
  • 138.Bellessort B, Bachelot A, Heude É, Alfama G, Fontaine A, Le Cardinal M, Treier M, Levi G. Role of Foxl2 in uterine maturation and function. Hum Mol Genet. 2015;24(11):3092–3103. doi: 10.1093/hmg/ddv061. [DOI] [PubMed] [Google Scholar]
  • 139.Governini L, Carrarelli P, Rocha AL, Leo VD, Luddi A, Arcuri F, Piomboni P, Chapron C, Bilezikjian LM, Petraglia F. FOXL2 in human endometrium: Hyperexpressed in endometriosis. Reprod Sci. 2014;21(10):1249–1255. doi: 10.1177/1933719114522549. [DOI] [PubMed] [Google Scholar]
  • 140.Eozenou C, Vitorino Carvalho A, Forde N, Giraud-Delville C, Gall L, Lonergan P, Auguste A, Charpigny G, Richard C, Pannetier M, Sandra O. FOXL2 is regulated during the bovine estrous cycle and its expression in the endometrium is independent of conceptus-derived interferon tau. Biol Reprod. 2012;87(2):32. doi: 10.1095/biolreprod.112.101584. [DOI] [PubMed] [Google Scholar]
  • 141.Popovici RM, Betzler NK, Krause MS, Luo M, Jauckus J, Germeyer A, Bloethner S, Schlotterer A, Kumar R, Strowitzki T, von Wolff M. Gene expression profiling of human endometrial-trophoblast interaction in a coculture model. Endocrinology. 2006;147(12):5662–5675. doi: 10.1210/en.2006-0916. [DOI] [PubMed] [Google Scholar]
  • 142.Elbaz M, Hadas R, Bilezikjian LM, Gershon E. Uterine Foxl2 regulates the adherence of the Trophectoderm cells to the endometrial epithelium. Reprod Biol Endocrinol. 2018;16:12. doi: 10.1186/s12958-018-0329-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Assisted Reproduction and Genetics are provided here courtesy of Springer Science+Business Media, LLC

RESOURCES